Clazakizumab - CAS 1236278-28-6

Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].

Interleukin, SARS-CoV

Immunology/Inflammation, Microbiology/Virology

1236244

-20°C

Ice Packs

Inhibitory Antibodies